Apoptosis in cancer: from pathogenesis to treatment

被引:2173
作者
Wong, Rebecca S. Y. [1 ]
机构
[1] Int Med Univ, Sch Med & Hlth Sci, Div Human Biol, Kuala Lumpur 57000, Malaysia
关键词
Apoptosis; defective apoptotic pathways; carcinogenesis; treatment target; CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-2 FAMILY PROTEINS; CELLS IN-VITRO; PANCREATIC-CANCER; DOWN-REGULATION; BREAST-CANCER; LUNG-CANCER; HEMATOLOGIC MALIGNANCIES; THERAPEUTIC TARGETS; COLORECTAL-CANCER;
D O I
10.1186/1756-9966-30-87
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due to too much apoptosis, such as in the case of degenerative diseases while in others, too little apoptosis is the culprit. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not die. The mechanism of apoptosis is complex and involves many pathways. Defects can occur at any point along these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to anticancer drugs. Despite being the cause of problem, apoptosis plays an important role in the treatment of cancer as it is a popular target of many treatment strategies. The abundance of literature suggests that targeting apoptosis in cancer is feasible. However, many troubling questions arise with the use of new drugs or treatment strategies that are designed to enhance apoptosis and critical tests must be passed before they can be used safely in human subjects.
引用
收藏
页数:14
相关论文
共 104 条
[31]   The morphology of apoptosis [J].
Häcker, G .
CELL AND TISSUE RESEARCH, 2000, 301 (01) :5-17
[32]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[33]   Apoptosis: Corralling the corpses [J].
Hengartner, MO .
CELL, 2001, 104 (03) :325-328
[34]  
Hu YP, 2003, CLIN CANCER RES, V9, P2826
[35]   Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia [J].
Jensen, Markus ;
Engert, Andreas ;
Weissinger, Florian ;
Knauf, Wolfgang ;
Kimby, Eva ;
Poynton, Christopher ;
Oliff, Ira Anton ;
Rummel, Mathias J. ;
Oesterborg, Anders .
INVESTIGATIONAL NEW DRUGS, 2008, 26 (02) :139-149
[36]   Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells [J].
Kami, K ;
Doi, R ;
Koizumi, M ;
Toyoda, E ;
Mori, T ;
Ito, D ;
Kawaguchi, Y ;
Fujimoto, K ;
Wada, M ;
Miyatake, SI ;
Imamura, M .
SURGERY, 2005, 138 (02) :299-305
[37]   Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy [J].
Kang, Min H. ;
Reynolds, C. Patrick .
CLINICAL CANCER RESEARCH, 2009, 15 (04) :1126-1132
[38]  
Kerr J.F., 1991, APOPTOSIS MOL BASIS, V3, P5
[39]   APOPTOSIS - BASIC BIOLOGICAL PHENOMENON WITH WIDE-RANGING IMPLICATIONS IN TISSUE KINETICS [J].
KERR, JFR ;
WYLLIE, AH ;
CURRIE, AR .
BRITISH JOURNAL OF CANCER, 1972, 26 (04) :239-+
[40]   Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma [J].
Krepela, Evzen ;
Dankova, Petra ;
Moravcikova, Erika ;
Krepelova, Anna ;
Prochazka, Jan ;
Cermak, Jan ;
Schutzner, Jan ;
Zatloukal, Petr ;
Benkova, Kamila .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 35 (06) :1449-1462